Today's corporate news highlighted a dichotomy of significant strategic growth and severe operational setbacks. Rosebank Industries successfully raised £1.9 billion for two major US industrial acquisitions, and GSK completed its acquisition of RAPT Therapeutics to expand its immunology pipeline. Conversely, Surface Transforms announced the loss of its primary customer, General Motors, prompting an urgent strategic review due to severe financial implications. Other developments included Babcock International establishing a £3 billion Euro Medium Term Note Programme, Tanfield Group detailing legal challenges affecting a key investment, and CyanConnode extending a 'put up or shut up' deadline for a potential takeover bid.
Manufacturers of carbon fibre reinforced ceramic automotive brake discs, Surface Transforms SCE, confirmed a significant setback today. The company announced that General Motors, its largest customer, will re-source its brake disk supply from March 31, 2026. General Motors represented 84% of Surface Transforms' revenue in the last fiscal year and was under contract until 2030. The loss of this contract is expected to have a material impact on the company's trading capabilities, with management actively assessing the implications.
Athelney Trust ATY, an investor in small companies and junior markets, published its final results for the 12 months ended 31 December 2025. The statutory accounts for the period received an unqualified auditor's report, indicating no significant issues with the financial statements. The full Annual Report and Accounts are available for shareholders, offering a detailed review of the company's performance and strategic direction over the past year.
Tanfield Group TAN offered an update on its significant 49% stake in Snorkel International Holdings, an aerial work platform business. This investment is currently valued at £19.1 million, a substantial figure for Tanfield. The company noted that the outcome of ongoing US legal proceedings could have a material impact on this valuation, signaling potential financial risk or opportunity for the group depending on the resolution.
Rosebank Industries ROSE announced the successful completion of an institutional capital raise, securing approximately £1.9 billion. This significant funding was achieved through the issuance of 575,757,575 new ordinary shares at an issue price of £3.30 per share. Additionally, directors and senior employees subscribed for a further £12.3 million. The substantial capital injection is intended to finance the strategic acquisition of two market-leading US industrial businesses, MW Components and CPM, signaling a major expansion for Rosebank Industries.
Pharmaceutical giant GSK GSK confirmed the completion of its acquisition of RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on inflammatory and immunologic diseases. This strategic move strengthens GSK's pipeline with ozureprubart, a long-acting anti-IgE monoclonal antibody currently in Phase IIb clinical development for food allergies. The drug has the potential for less frequent dosing, which could improve patient compliance and expand treatment options for a broader patient population.
System1 Group SYS1 announced a significant board change, confirming the immediate departure of director John Kearon. This follows yesterday's disclosure that Mr. Kearon sold his entire 23.01% shareholding in the company to Brave Bison Group. The change marks a notable shift in leadership and a considerable alteration in System1 Group's ownership structure.
Vp VP., the equipment rental specialist, reported a notable director share purchase. Richard Smith, a Non-Executive Director, acquired 10,000 ordinary shares in the company at a price of 486.33 pence per share. This transaction, totaling over £48,000, signals a significant display of insider confidence in the company's valuation and future performance.
Babcock International Group BAB confirmed the publication of its base prospectus for a substantial £3,000,000,000 Euro Medium Term Note Programme. This financial framework will enable the company to issue various types of debt securities over time, providing significant flexibility for its capital structure and funding requirements. The establishment of such a large program is a strategic financial move for the global aerospace and defence company.
CyanConnode Holdings CYAN informed the market of an extension to the 'put up or shut up' deadline concerning a possible all-cash offer from Esyasoft Holding. This extension indicates that discussions regarding the potential takeover are ongoing. Shareholders will be awaiting further updates as the negotiation period continues, highlighting the strategic uncertainty and potential for a change of ownership.